ReNeuron, a developer of cell-based therapeutics, is pleased to announce that it is partnering with Cardiff University under a new grant-funded collaboration utilising ReNeuron’s exosome-based drug delivery technology platform.
The grant has been awarded under Innovate UK’s Knowledge Transfer Partnership and will fund a £250,000 collaborative programme of research to be undertaken by ReNeuron and the European Cancer Stem Cell Research Institute at Cardiff University. The research programme will develop novel systems to enable the delivery of therapeutic nucleic acids, such as small interfering RNA (siRNA), across the blood brain barrier using ReNeuron’s CTX stem cell-derived exosomes.
Delivering therapeutic compounds across the blood brain barrier remains a significant challenge – current delivery methods focus on easier-to-reach areas of the body. Earlier data generated at ReNeuron have already demonstrated the ability of its CTX-derived exosomes to cross the blood brain barrier. The ambition of the collaboration between ReNeuron and the University of Cardiff is to open up a new route for the delivery of therapeutic agents that have previously failed to target the brain.
Commenting on the grant award, Dr Randolph Corteling, Head of Research at ReNeuron, commented: “We and our collaborators are delighted to have won this latest grant from Innovate UK. We are very excited about the potential of our exosome technology platform to deliver therapeutic compounds to the brain and thereby to make a real step-change in the development of treatments against hard-to-target disorders of the central nervous system.”
Source – ReNeuron